Leaflet: information for the patient
Kanilad50 mg film-coated tablets EFG
Kanilad 100 mg film-coated tablets EFG
Kanilad 150 mg film-coated tablets EFG
Kanilad200 mg film-coated tablets EFG
lacosamide
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the leaflet
5 Conservation of Kanilad
What is Kanilad
Kanilad contains lacosamide, which belongs to a group of medications called antiepileptic medications. These medications are used to treat epilepsy.
What Kanilad is used for
.
Do not take Kanilad
(including those listed in section 6). If you are unsure, consult your doctor.
Do not take Kanilad if any of the above applies to your case. If you are unsure, consult your doctor or pharmacist before taking this medication.
Warnings and precautions
Consult your doctor before starting to use Kanilad if:
If any of the above applies to your case (or you are unsure), consult your doctor or pharmacist before taking Kanilad.
If you are taking Kanilad, consult your doctor if you experience a new type of seizure or worsening of existing seizures.
If you are taking lacosamide and experience symptoms of abnormal heartbeat (such as slow, fast, or irregular heartbeat, palpitations, shortness of breath, dizziness, fainting), consult your doctor immediately (see section 4)
Children
Kanilad is not recommended in children under 2 years of age with epilepsy characterized by the onset of partial seizures or in children under 4 years of age with primary generalized tonic-clonic seizures. This is because it is not yet known whether it is effective and safe for children in this age group.
Other medications and Kanilad
Tell your doctor or pharmacist if you are taking, have recently taken, or may take any other medication.
In particular, tell your doctor or pharmacist if you are taking any of the following medications that affect the heart. The reason is that Kanilad may also affect the heart.
If any of the above applies to your case (or you are unsure), talk to your doctor or pharmacist before taking Kanilad.
Also, inform your doctor or pharmacist if you are taking any of the following medications.
The reason is that they may also increase or decrease the effect of Kanilad in your body.
If any of the above applies to your case (or you are unsure), talk to your doctor or pharmacist before taking Kanilad.
Taking lacosamide with alcohol
As a precaution, do not take this medication with alcohol.
Pregnancy and breastfeeding
Women of childbearing age should discuss the use of contraceptives with their doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Kanilad is not recommended if you are pregnant, as the effects of Kanilad on pregnancy and the fetus are not known.
It is not recommended to breastfeed a baby while taking Kanilad, as Kanilad passes into breast milk.
Seek immediate advice from your doctor if you are pregnant or plan to become pregnant. They will help you decide whether to take Kanilad or not.
Do not stop treatment without talking to your doctor first, as this may increase the risk of seizures (crises). Worsening of your condition may also harm the fetus.
Driving and using machines
Do not drive, ride a bicycle, or use any tool or machine until you know if this medication affects you. The reason is that lacosamide may cause dizziness or blurred vision.
Follow the administration instructions of this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again. Another form of this medication may be more suitable for children; consult your doctor or pharmacist.
Taking Kanilad
Normally, you will start taking a low dose every day and your doctor will gradually increase the dose over several weeks. When you reach the dose that works well for you, called the "maintenance dose", you will take the same amount every day. This medication is used as long-term treatment. You should continue taking this medication until your doctor tells you to stop.
How much to take
The following are the usual recommended doses of this medication for different age and weight groups. Your doctor may prescribe a different dose if you have kidney or liver problems.
Adolescents and children weighing 50 kg or more and adults
When taking Kanilad alone:
The usual starting dose is 50 mg twice a day.
Your doctor may also prescribe a starting dose of 100 mg of lacosamide twice a day.
Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 300 mg twice a day.
When taking Kanilad with other antiepileptic medications:
The usual starting dose is 50 mg twice a day.
Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 200 mg twice a day.
If you weigh 50 kg or more, your doctor may start lacosamide treatment with a single "loading dose" of 200 mg. Then you will start taking the continuous maintenance dose 12 hours later.
Children and adolescents weighing less than 50 kg
The dose depends on body weight. Treatment is usually started with the syrup and only changed to tablets if the patient is able to take them and get the correct dose with tablets of different doses. The doctor will prescribe the pharmaceutical form that best suits you.
If you take more Kanilad than you should
If you have taken more lacosamide than you should, consult your doctor immediately. Do not attempt to drive. You may experience:
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Kanilad
If you stop taking Kanilad
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone experiences them.
Side effects on the nervous system, such as dizziness, may be greater after a single "loading dose".
Tell your doctor or pharmacist if you experience any of the following effects:
Very common: may affect more than 1 in 10 patients
Common: may affect up to 1 in 10 patients
Uncommon: may affect up to 1 in 100 patients
Frequency not known: cannot be estimated from available data
Other side effects in children
Additional side effects observed in children were fever (pyrexia), runny nose (nasopharyngitis), sore throat (pharyngitis), decreased appetite, behavioral changes, not acting as they normally do (abnormal behavior), and lack of energy (lethargy). Drowsiness (somnolence) is a very common side effect in children and may affect more than 1 in 10 children.
Reporting side effects
If you experience any side effect, consult your doctor or pharmacist, even if it is a side effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the box and blister pack after "EXP". The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition ofKanilad
The active ingredient is lacosamide.
Each Kanilad 50 mg tablet contains 50 mg of lacosamide.
Each Kanilad 100 mg tablet contains 100 mg of lacosamide.
Each Kanilad 150 mg tablet contains 150 mg of lacosamide.
Each Kanilad 200 mg tablet contains 200 mg of lacosamide.
Core of the tablet: microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylcellulose (low substituted), anhydrous colloidal silica, crospovidone (Type A), magnesium stearate.
Coating:
Poly (vinyl alcohol), macrogol (3350), talc, titanium dioxide (E171).
Aluminum lake indigo carmine (E132) (50 mg and 200 mg film-coated tablets).
Red iron oxide (E172) (50 mg and 150 mg film-coated tablets).
Black iron oxide (E172) (50 mg and 150 mg film-coated tablets).
Yellow iron oxide (E172) (100 mg and 150 mg film-coated tablets).
Appearance of the product and container contents
Kanilad 50 mg are oval, pink, film-coated tablets marked with "I73" on one side and smooth on the other.
The average size of the tablets is 10.4 x 4.9 mm.
Kanilad 100 mg are oval, dark yellow, film-coated tablets marked with "I74" on one side and smooth on the other.
The average size of the tablets is 13.0 x 6.0 mm.
Kanilad 150 mg are oval, peach, film-coated tablets marked with "I75" on one side and smooth on the other.
The average size of the tablets is 15.0 x 7.0 mm.
Kanilad 200 mg are oval, blue, film-coated tablets marked with "I76" on one side and smooth on the other.
The average size of the tablets is 16.5 x 7.7 mm.
PVC/PVDC sealed with an aluminum foil.
Kanilad is available in packs of 7, 14, 28, 56, and 168 film-coated tablets.
Only some pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Medochemie Ltd.
1-10 Constantinoupoleos Street
3011 Limassol
Cyprus
Manufacturer
Medochemie Ltd. Facility A-Z
2 Michael Erakleous street, Agios Athanassios,
Industrial Area, CY-4101 Limassol
Cyprus
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Medochemie Iberia S.A., Sucursal en España
Avenida de las Águilas, nº 2 B; planta 5 oficina 6,
28044 Madrid
Spain
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Bulgaria: ??????? 50 mg, 100 mg, 150 mg & 200 mg ????????? ????????
Croatia: KANILAD 50 mg, 100 mg, 150 mg & 200 mg filmom obložene tablete
Cyprus: KANILAD 50 mg, 100 mg, 150 mg & 200 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α
Czech Republic: KANILAD
Estonia: KANILAD
Germany: KANILAD 50 mg, 100 mg, 150 mg & 200 mg Filmtabletten
Greece: KANILAD 50 mg, 100 mg, 150 mg & 200 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α
Latvia: KANILAD 50 mg, 100 mg, 150 mg & 200 mg apvalkotas tabletes
Lithuania: KANILAD 50 mg, 100 mg, 150 mg & 200 mg plevele dengtos tabletes
Malta: KANILAD 50 mg, 100 mg, 150 mg & 200 mg film-coated tablets
Romania: KANILAD 50 mg, 100mg, 150 mg & 200 mg comprimate filmate
Slovakia: KANILAD 50 mg, 100 mg, 150 mg & 200 mg filmom obalené tablety
Date of last revision of thisleaflet:September 2022
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The average price of KANILAD 100 mg FILM-COATED TABLETS in October, 2025 is around 65.78 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.